Treatment of Tumors of the Choroid Plexus Epithelium
NCT00500890
Terminated
The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve choroid plexus tumor treatment through better understanding of the tumor biology and through increased knowledge about the benefit of specific treatment elements. Specific Objectives: The study will h... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/21/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Choroid Plexus Tumors
Register for Updates
Hematopoietic Stem Cell Transplant in Devic's Disease
NCT00787722
Completed
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system), followed by return of previously collected patient's stem cells will result in improvement in Devic's disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense ch... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
02/17/2020
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: Devic's Disease
Register for Updates
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
NCT00007813
Completed
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphami... Read More
Gender:
ALL
Ages:
35 years and below
Trial Updated:
02/14/2020
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Register for Updates
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00918723
Completed
This phase I/II trial studies the side effects and best dose of vorinostat when given together with fludarabine phosphate, cyclophosphamide, and rituximab and to see how well they work in treating patients with previously untreated B-cell chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington +1 locations
Conditions: Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Register for Updates
Stem Cell Transplant for Hemoglobinopathy
NCT00176852
Completed
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies. The researchers hypothesize that these regimens will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease. Regimen A2 has replaced Regimen A in this study. Two patients were treated on Regimen A but did not have evidence of initial engraftment thus triggering the stopping rule for that... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
02/13/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Register for Updates
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
NCT01749293
Terminated
Allogeneic stem cell transplantation is a potentially curative treatment for patients with many hematologic malignancies (e.g. leukemia, lymphoma, and myeloma with high risk of relapse). This process requires a suitable donor. The best case scenario involves an Human Leukocyte Antigen (HLA) matched sibling donor. However, this type of donor is not always available. Donor registries can provide another source for matched unrelated donors, but this may take valuable time delaying treatment for the... Read More
Gender:
ALL
Ages:
Between 10 years and 75 years
Trial Updated:
02/12/2020
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Hematologic Malignancies
Register for Updates
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
NCT00727441
Completed
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine therapy together with cyclophosphamide may kill more tumor cells. It is not yet known whether vaccine therapy is more effective with or without cyclophosphamide in trea... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/12/2020
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Partial Breast Irradiation With Chemotherapy
NCT00278109
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cyclophosphamide and doxorubicin after surgery may kill any tumor cells that remain. PURPOSE: This phase I/II trial is studying the side effects of radiation therapy when given together with cycl... Read More
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
02/11/2020
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NCT01438177
Terminated
This pilot phase II trial studies how well giving bortezomib and cyclophosphamide together with chloroquine works in treating patients with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2020
Locations: NYU Cancer Institute, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT00305760
Completed
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killi... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2020
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
NCT00939653
Terminated
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/07/2020
Locations: Childrens Hospital Los Angeles, Los Angeles, California +3 locations
Conditions: Relapsed Acute Myelogenous Leukemia
Register for Updates
NK Cells in Cord Blood Transplantation
NCT01619761
Unknown
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies. Giving chemotherapy with or without total body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the pa... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
02/07/2020
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Register for Updates